Jump to content

LUNGevity Blog - KRAS: How It Started vs. How It’s Going


NikoleV

Recommended Posts

KRAS: How It Started vs. How It’s Going

Posted on April 21, 2022

Dr. Amy Moore and Dr. Upal Basu Roy

On May 28, 2021, the United States Food & Drug Administration (FDA) approved sotorasib as the first targeted therapy for patients with KRAS G12C-positive non-small cell lung cancer (NSCLC). Both researchers and patients celebrated this historic breakthrough, which had been a goal since discovering the KRAS oncogene 40 years ago. KRAS is a leading driver mutation in various forms of cancer. Still, targeting KRAS had failed for nearly four decades, leading many to believe that it was “undruggable.”

In the nearly one year since this first FDA approval, advances in the KRAS space have continued to grow rapidly. Here we reflect on the past year and look into our crystal ball to predict where this field is going.

Read more of the blog here:

https://www.lungevity.org/blogs/kras-how-it-started-vs-how-it’s-going

 

Link to comment
Share on other sites

Archived

This topic is now archived and is closed to further replies.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.